Advanced Renal Cell Carcinoma

Long-Term Follow-Up of Pembrolizumab Plus Axitinib in Advanced RCC: Efficacy and Biomarker Insights From KEYNOTE-426
New data on long-term outcomes from phase 3 of KEYNOTE-426 included efficacy and prespecified exploratory biomarker analyses.

Latest News

Knowledge Hub Spotlights

Curated clinical content based on conditions, therapies, and technologies

Renal Cell Carcinoma
Renal Cell Carcinoma

Conference Coverage

Trending